What is the current Price Target for the ARCA biopharma, Inc. stock?

The average ARCA biopharma, Inc. target price is $480.00. This is 1,820.77% higher than the current stock price. 1 Analyst has issued a ARCA biopharma, Inc. price target 2025.

How high will the ARCA biopharma, Inc. stock rise?

No reliable answer can be given as to how high the ARCA biopharma, Inc. stock will rise. The performance of stocks, including the ARCA biopharma, Inc. stock, depends on a variety of factors, such as the general economic situation, the company's business results, investor expectations and global events.

What's going on with the ARCA biopharma, Inc. stock today?

The performance of ARCA biopharma, Inc. stock on any given day can be influenced by various factors, such as market conditions, industry trends, company news and global events.

Why did the ARCA biopharma, Inc. stock fall?

The decline in ARCA biopharma, Inc. stock may be due to a variety of factors, such as market conditions, industry trends, company news, macroeconomic events or changes in investor expectations. It is important to note that stock markets are inherently volatile and the performance of an individual stock on any given day is not necessarily indicative of its long-term performance.

What is a price target?

A price target is an estimate by an analyst or investment bank of where a company's stock price could be in a certain period of time, usually 12 months.

ARCA biopharma, Inc. Forecast, price target & analysts

$24.99

2.80%

Nasdaq, Fri, Sep 06 2024

ISIN

US00211Y4070

Symbol

ABIO

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Biotechnology

Overview Dividends Analysts Charts News Strategies

ARCA biopharma, Inc. Target price 2024 - Analyst rating & recommendation

ARCA biopharma, Inc. Classifications & Recommendation:

Buy

100%

ARCA biopharma, Inc. Price Target

Target Price	$480.00
Price	$24.99
Potential	1,820.77% register free of charge
Number of Estimates	1

	1 Analyst has issued a ARCA biopharma, Inc. price target 2025. The average ARCA biopharma, Inc. target price is $480.00. This is 1,820.77% register free of charge higher than the current stock price.
	A rating was issued by 1 analysts: 1 Analysts recommend ARCA biopharma, Inc. to buy, 0 to hold and 0 to sell.
	Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
	Analyst Estimates: Analysts believe that the ARCA biopharma, Inc. stock has an average upside potential 2025 of 1,820.77% register free of charge . Most analysts recommend the ARCA biopharma, Inc. stock at Purchase.

Earnings per share, P/E ratio and EV/sales Estimates 2024, 2025 to 2028

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually

	Dec '23	2024 Estimates
Earnings Per Share $	-4.44	-14.04
	543.48%	216.22%
P/E		negative

1 Analysts have issued a ARCA biopharma, Inc. forecast for earnings per share. The average ARCA biopharma, Inc. <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is

Unlock

. This is

Unlock

than earnings per share in the financial year 2023. The highest <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS forecast is

Unlock

, the lowest is

Unlock

This results in the following potential growth metrics and future valuations:

2023	$-4.44	543.48%
2024	$-14.04 216.22% Unlock
2025	$-16.92 20.51% Unlock
2026	$-22.08 30.50% Unlock
2027	$-30.24 36.96% Unlock
2028	$-39.12 29.37% Unlock

Current	-4.19	9.50%
2024	-1.78 57.52% Unlock
2025	-1.48 16.85% Unlock
2026	-1.13 23.65% Unlock
2027	-0.83 26.55% Unlock
2028	-0.64 22.89% Unlock

ARCA biopharma, Inc....

Discover more stocks with a high price target

Valneva 196.57%

CureVac N.V. 194.05%

Plug Power Inc. 152.17%

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now